Psychedelics & Mental Health Treatment
•10 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (10)
| Company | Market Cap | Price |
|---|---|---|
|
ATAI
Atai Life Sciences N.V.
ATAI's core pipeline focuses on psychedelic-assisted mental health therapies, aligning with psychedelics & mental health treatment.
|
$1.17B |
$5.86
+1.30%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's lead asset MM120 is a psychedelic-based neuropsychiatric therapy targeting GAD and MDD, a core product line in MindMed's pipeline.
|
$1.07B |
$14.21
+6.12%
|
|
GHRS
GH Research PLC
GH Research directly develops psychedelic-based therapies for mental health, aligning with Psychedelics & Mental Health Treatment.
|
$745.04M |
$14.30
+14.04%
|
|
CMPS
COMPASS Pathways plc
Directly describes COMPASS Pathways' focus on psychedelic-based mental health therapies (COMP360) and TRD/PTSD programs.
|
$591.31M |
$6.31
+0.16%
|
|
CYBN
Cybin Inc.
Cybin's core offerings are psychedelic therapeutics for mental health, aligning with Psychedelics & Mental Health Treatment.
|
$145.21M |
$7.28
+1.39%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's ketamine-based and psychedelic-assisted mental health strategies align with Psychedelics & Mental Health Treatment.
|
$53.60M |
$3.08
+2.15%
|
|
IXHL
Incannex Healthcare Limited
PSX-001 is a psychedelic-assisted therapy for Generalized Anxiety Disorder, aligning with Psychedelics & Mental Health Treatment.
|
$11.10M |
$0.38
-6.17%
|
|
CMND
Clearmind Medicine Inc.
CMND is developing psychedelic-derived therapeutics for mental health and substance-use disorders (e.g., Alcohol Use Disorder); aligns with Psychedelics & Mental Health Treatment.
|
$3.17M |
$0.76
-16.75%
|
|
SILO
Silo Pharma, Inc.
Psychedelics & Mental Health Treatment captures the psychedelics-focused therapeutic strategy highlighted by SPC-15 and related programs.
|
$2.43M |
$0.55
-1.57%
|
|
ENVB
Enveric Biosciences, Inc.
Company operates in the psychedelics and mental health treatment space, developing non-hallucinogenic neuroplastogens for psychiatric indications.
|
$1.17M |
$5.62
-8.32%
|
Loading company comparison...
Loading industry trends...
Loading research report...
